GlassScriptPhysician profile
Jennifer Bunn
NPI 1578100442
$1,355.69
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $737 · 2023: $364 · 2024: $18.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $171.99 | 2021-2023 | Padcev |
| Incyte Corporation | $136.98 | 2022 | |
| Genzyme Corporation | $119.40 | 2022-2023 | |
| Janssen Biotech, INC. | $119.28 | 2022 | |
| Janssen Scientific Affairs, LLC | $109.77 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $95.09 | 2021-2023 | Epkinly, Imbruvica |
| Novartis Pharmaceuticals Corporation | $92.19 | 2021-2023 | |
| Amgen INC. | $54.17 | 2021-2023 | Kyprolis |
| Astrazeneca Pharmaceuticals LP | $50.06 | 2022 | |
| Daiichi Sankyo INC. | $49.23 | 2021-2022 | |
| Gilead Sciences, INC. | $40.74 | 2023 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $35.42 | 2022 | |
| Merck Sharp & Dohme LLC | $34.93 | 2022 | |
| Clovis Oncology, INC. | $28.02 | 2021-2022 | |
| Tg Therapeutics, INC. | $21.46 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $20.25 | 2022 | |
| Karyopharm Therapeutics INC. | $20.11 | 2022 | |
| Cti Biopharma Corp. | $19.99 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $18.00 | 2024 | Pyrukynd |
| Celgene Corporation | $17.79 | 2023 | Reblozyl |
| Beigene USA, INC. | $17.62 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.58 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.53 | 2023 | Libtayo |
| Pharmacosmos Therapeutics INC. | $17.17 | 2023 | Monoferric |
| Mirati Therapeutics, INC. | $16.87 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.